Global Initiative For Treatment of major chronic diseases

Shanthi Mendis

MD FRCP FACC

Coordinator

Cardiovascular Diseases

World Health
Organization

Global Initiative For Treatment of major chronic diseases

- **Rationale**
- **Objectives**
- **Processes / activities**
- **Expected outcomes**

Rationale

Mortality
- **CVD**   **16.7 million**
- **Diabetes**   **0.98 million**
- **CRD**   **3.7 million**
- **Cancer**   **7.0 million**

42% of NCD burden
- **CVD**
- **Diabetes**
- **CRD**
- **Cancer**

Number of Cardiovascular Deaths Projected to 2020

Millions

20000000
18000000
16000000
14000000
12000000
10000000
8000000
6000000
4000000
2000000
0

2002   2020   Lower Income   2002   2020   Higher Income

The potential of secondary prevention

	RR reduction	2-year event rate
• None	-----	8.0%
• Aspirin	25%	6.0%
• B B	25%	4.5%
• Statin	30%	3.0%
• ACEI	25%	2.3%

Secondary Prevention of CHD

Overall Percentage in 10 countries

Drugs

Aspirin — 66
ACEI — 53
BB — 45
Statins — 29

Percentage (0, 20, 40, 60, 80, 100)

WHO PREMISE 2003

Department of Chronic Diseases and Health Promotion

World Health Organization

Prevention and Control of CVD

- **Primary prevention**

- **Secondary prevention**

World Health
Organization

Global Initiative For Treatment of major chronic diseases

- **CHD/CeVD/RHD**
- **Bronchial asthma**
- **Diabetes**
- **Glaucoma**
- **Cancer (palliative care)**

World Health
Organization

Objectives

To improve

- **Health outcomes**
- **Efficiency**
- **Equity**

World Health
Organization

Is affordability a problem?

- **Pakistan : statin 1 month supply = one third the monthly wage**

- **Kenya : Furosemide generic form is 2.5% that of the originator brand form**

World Health Organization

Kg of (rice/yam) that can be purchased with money required for buying the cheapest statin for 1 week

	Kg
• **China**	**28**
• **Egypt**	**34**
• **Georgia**	**51**
• **Indonesia**	**5**
• **Iran**	**1.4**
• **Mozambique**	**4.7**
• **Nepal**	**13**
• **Pakistan**	**24**
• **Uruguay**	**35**

China: 28 Kg of rice can be bought for cost of 1 week supply of statins

World Health Organization

World Health Survey

- **Diagnosed as angina   (4%-14%)**
- **On Rx   (14%-60%)**
- **Diagnosed angina –aspirin (1%-20%)**
- **Diagnosed angina –BB   (<5%)**


- **(Bangladesh, Burkina Faso, China, India, Malawi, Malaysia, Mexico, Nepal, Sri Lanka , Vietnam)**

Determinants of effective drug treatment

Affordability

Accessibility

Evidence based prescription

Determinants of effective drug treatment

Appropriate use

Quality and efficacy

World Health Organization

Players and Processes

Incentives
CME
Doctors
Referral links
Patients/Families

Manufacture
Procurement
Distribution
Regulations

Affordability

Evidence based prescription

Accessibility

Appropriate use

Quality and efficacy

Financing
Public/private
Reimbursement
Insurance
Research /development

Department of Chronic Diseases and Health Promotion

World Health
Organization

How ?

- **Assess situation**
- **Identify barriers**
- **Direct intervention**
- **Advocate for change**

World Health Organization

Price of Medicines Survey

The survey will gather information on:

- **Procurement / final prices**
- **Prices in different parts of the country**
- **Relative prices of proprietary / generic**
- **Affordability of treatment for ordinary people**
- **International difference in prices**

World Health
Organization

Priority list of drugs

- **Aspirin**
- **Thiazides**
- **Betablockers**
- **ACEI**
- **Statin**
- **Metformin**
- **Glibenclamide**
- **Insulin**
- **Salbutamol**
- **Beclometasone/oral steroids**
- **Aminophylline**
- **Benzathine penicillin**
- **Beta blocker eye drops**
- **Morphine**

(Model list / PHC / minimum monitoring/Safety)

-

World Health Organization

Are there mechanisms to reduce drug prices ?

- **Ensure generic medicines**
- **Seek volume discounts for group purchases**
- **Open competitive purchasing methods**
- **Monitor prices paid by other purchasers**
- **Eliminate duties and taxes and add-ons**
- **Partnership arrangements**

World Health
Organization

Expected outcomes

- **Reduce cost of drugs**
- **Improve accessibility**
- **Efficient procurement practices**
- **Evidence based prescriptions**
- **National programs addressing Rx needs through equitable programs**
- **Partnership arrangements with industry**
- **Enhance local production of generics**

World Health
Organization

Global Initiative For Treatment of major chronic diseases

Appropriate use

Quality & efficacy

prescription

Accessibility

Affordability

GIFT

World Health Organization